India, March 30 -- Eli Lilly and Co.'s (LLY) Phase 2 trial results revealed that lepodisiran significantly lowered lipoprotein(a) levels, a genetically inherited heart disease risk factor. At the highest tested dose, the drug achieved an impressive reduction of nearly 94% from baseline in adults with elevated levels.
Lepodisiran is an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.
According to the company, lepodisiran significantly reduced Lp(a) levels in the Phase 2 ALPACA study by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint. Par...